BrightGene Bio-Medical Technology (Suzhou) Co., Ltd.

Company Description

A research-based pharmaceutical companyBrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as BrightGene Bio-Medical Technology (Suzhou) Co., Ltd.ll as special generic APIs and FDFs with primary strategic focus on the regulated market and Chinese market.Established in 2001, BrightGene boasts cutting- edging R&D expertise and commercial manufacturing capabilities to serve our patients and clients around the globe.We have an exciting and very promising innovative pipeline including immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, orally available oxyntomodulin analog for NASH and novel non-antibody dependent tumor targeting conjugates for brain and other types of cancer.In parallel, we have also developed a special generic pipeline of extremely challenging molecules like Eribulin, Trabectedin, Fondaparinux, Caspofungin and non-biological macromolecules such as Ferumoxytol and Ferric pyrophosphate citrate.We pride ourselves in exceptional R&D capability and robust project execution. Combining high productivity and cost-effective resources, along with unmatched regulatory and technical know-how, BrightGene is uniquely positioned to compete in the global pharmaceutical industry, particularly the fast growing specialty pharmaceutical sector.

Company Information

  • Telephone:
  • Operational Address:Bldg. C25, Nami Tech Park, No. 218, Xinghu Street, Ind. Zone, Suzhou, Jiangsu, China (Mainland)
  • Business Type:Manufacturer, Trading Company
  • Year Established:2001
  • Main Products:API,Intermediates,Chemical,Iron Supplements, Anti-Tumor, ADC Cytotoxic Payload, Diabetes,Animal Healthcare,Contraception, Multiple Sclerosis, Immunology,Cardiovascular,Anti-HBV, Anti-Infectio,
  • Location:Jiangsu, China (Mainland)
  • Website:Visit website

Product

  • Micafungin,208538-73-2,Anti-infection
  • Caspofungin Acetate,179463-17-3,Anti-infection
  • Micafungin intermediate,MFA,168110-44-9,Anti-infection
  • Anidulafungin,166663-25-8,Antifungal
  • Pneumocandin BO,135575-42-7,Caspofungin intermediate(KBO),Anti-infection
  • Echinocandin BO,79411-15-7,Antifungal
  • Posaconazole(PO),171228-49-2,Anti-infection
  • Posaconazole intermediate(POA),149809-43-8,Anti-infection
  • Posaconazole intermediate (POB),184177-83-1,Antifungal
  • Dalbavancin,171500-79-1,Anti-infection
  • Oritavancin,171099-57-3,Antibacterial
  • Fidaxomicin,873857-62-6,Antibacterial
  • Moxidectin,113507-06-5,Animal Healthcare,EP/USP
  • Entecavir Anti-HBV 209216-23-9
  • Doramectin 117704-25-3 ,Animal Healthcare,EP/USP
  • Doramectin,117704-25-3,Animal Healthcare,EP/USP
  • Entecavir intermediate(ET1)
  • Milbemycin Oxime,129496-10-2,Animal Healthcare,EP/USP
  • Selamectin,165108-07-6,Animal Healthcare,EP/USP
  • Entercavir Monohydrate,209216-23-9,Anti-HBV,EP/USP
  • Entercavir intermediate(ETA),142217-81-0,Anti-HBV,EP/USP
  • Moxidectin,113507-06-5,Animal Healthcare,EP/USP
  • Milbemycin Oxime,129496-10-2,Animal Healthcare,EP/USP
  • Fondaparinux Sodium,114870-03-0,Cardiovascular,EP/USP
  • Argatroban,141396-28-3,Cardiovascular,EP/USP
  • Ferric Carboxymaltose,9007-72-1,Iron Supplement,EP/USP
  • Fondaparinux Sodium intermediate(FSC) ,114903-05-8,Cardiovascular,EP/USP
  • Ansamitocin P3,66547-09-9,ADC Cytotoxic Payload,EP/USP
  • Ascomycin,11011-38-4,Immunology,EP/USP
  • Trabectedin,114899-77-3,Anti-Tumor,Oncology,EP/USP
  • Maytansinol,57103-68-1,Antibody-drug Conjugate,EP/USP
  • DM-1,139504-50-3,ADC Cytotoxic Payload,EP/USP
  • DM-4,799840-96-3,ADC Cytotoxic Payload,Antibody-drug Conjugate,EP/USP
  • MMAE (Monomethyl auristatin E),474645-27-7,ADC Cytotoxic Payload,Antibody-drug Conjugate,EP/USP
  • MMAF,745017-94-1,Antibody-drug Conjugate,ADC Cytotoxic Payload,EP/USP
  • Pimecrolimus,137071-32-0,Immunology,Oncology,EP/USP
Countries   China   India   Indonesia   Malaysia   Pakistan   Turkey   United Kingdom   United States   All Countries